Prevention and Control of Meningococcal Disease

Recommendations of the Advisory Committee on Immunization Practices (ACIP)

INSIDE: Continuing Education Examination

The *MMWR* series of publications is published by the Coordinating Center for Health Information and Service, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333.

CONTENTS

Disclosure of Relationship

CDC, our planners, and our content experts wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters. Presentations will not include any discussion of the unlabeled use of a product or a product under investigational use.

Prevention and Control of Meningococcal Disease

Recommendations of the Advisory Committee on Immunization Practices (ACIP)

Prepared by
Oleg O. Bilukha, MD, PhD
Nancy Rosenstein, MD
Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases

Summary

In January 2005, a tetravalent meningococcal polysaccharide-protein conjugate vaccine ([MCV4] Menactra,™ manufactured by Sanofi Pasteur, Inc., Swiftwater, Pennsylvania) was licensed for use among persons aged 11–55 years. CDC's Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination of young adolescents (defined in this report as persons aged 11–12 years) with MCV4 at the preadolescent health-care visit (at age 11–12 years). Introducing a recommendation for MCV4 vaccination among young adolescents might strengthen the role of the preadolescent visit and have a positive effect on vaccine coverage among adolescents. For those persons who have not previously received MCV4, ACIP recommends vaccination before high-school entry (at approximately age 15 years) as an effective strategy to reduce meningococcal disease incidence among adolescents and young adults. By 2008, the goal will be routine vaccination with MCV4 of all adolescents beginning at age 11 years. Routine vaccination with meningococcal vaccine also is recommended for college freshmen living in dormitories and for other populations at increased risk (i.e., military recruits, travelers to areas in which meningococcal disease is hyperendemic or epidemic, microbiologists who are routinely exposed to isolates of Neisseria meningitidis, *patients with anatomic or functional asplenia, and patients with terminal complement deficiency). Other adolescents, college students, and persons infected with human immunodeficiency virus who wish to decrease their risk for meningococcal disease may elect to receive vaccine.*

This report updates previous reports from ACIP concerning prevention and control of meningococcal disease. It also provides updated recommendations regarding use of the tetravalent meningococcal polysaccharide vaccine (MPSV4) and on antimicrobial chemoprophylaxis.

Introduction

Neisseria meningitidis has become a leading cause of bacterial meningitis in the United States after dramatic reductions in the incidence of *Streptococcus pneumoniae* (*1*) and *Haemophilus influenzae* type b (Hib) (*2*) infections have been achieved as a result of using conjugate vaccines. CDC's Advisory Committee on Immunization Practices (ACIP) previously recommended a tetravalent polysaccharide vaccine (Menomune®-A,C,Y,W-135, manufactured by Sanofi Pasteur, Inc., Swiftwater, Pennsylvania) for use among certain populations at increased risk, including travelers to countries with epidemic or hyperendemic meningococcal disease, persons who have certain medical conditions (i.e., terminal complement component deficiencies and anatomic or functional asplenia), and laboratory personnel who are routinely exposed to *N. meningitdis* in solutions that might be aerosolized (*3*). Use of this vaccine also was recommended for control of meningococcal disease outbreaks (*4*). Recommendations permitting use of MPSV4 among college freshmen have been published previously (*5*).

The new tetravalent A, C, Y, W-135 conjugate vaccine (Menactra™, manufactured by Sanofi Pasteur, Inc.) licensed for persons aged 11–55 years should become a key addition to existing meningococcal disease prevention measures. This report provides ACIP's recommendations on prevention and control of meningococcal disease, including recommendations on use of the new tetravalent conjugate vaccine (MCV4) as well as updated recommendations on use of the polysaccharide vaccine (MPSV4) and on antimicrobial chemoprophylaxis.

Background

Epidemiology of Meningococcal Disease

Each year, an estimated 1,400–2,800 cases of meningococcal disease occur in the United States, a rate of 0.5–1.1/100,000 population (CDC, unpublished data, 2004). *N. meningitidis* colonizes mucosal surfaces of nasopharynx and is transmitted through direct contact with large droplet respiratory secretions from the patients or asymptomatic carriers. Humans are the only host. Despite the continued sensitivity of meningococcus to multiple widely available antibiotics, including penicillin (*6,7*), the case-fatality ratio for meningococcal disease is 10%–14% (CDC, unpublished data, 2004). Meningococcal disease also causes substantial morbidity; 11%–19% of survivors have sequelae (e.g., neurologic disability, limb loss, and hearing loss) (*8,9*). During 1991–2002, the highest rate of meningococcal disease (9.2/100,000) occurred among infants aged <1 year; the rate for persons aged 11–19 years (1.2/100,000) also was higher than that for the general population (Figure 1). Although rates of disease are highest among children aged <2 years, 62% of meningococcal disease in the United States occurs among persons aged ≥11 years (CDC, unpublished data, 2004).

In the United States, >98% of cases of meningococcal disease are sporadic; however, since 1991, the frequency of localized outbreaks has increased (*10,11*). The proportion of meningococcal cases caused by serogroup Y increased from 2% during 1989–1991 (*12*) to 37% during 1997–2002 (CDC, unpublished data, 2004). Serogroups B, C, and Y are the major causes of meningococcal disease in the United States, each being responsible for approximately one third of cases.

The proportion of cases caused by each serogroup varies by age group. Among infants aged <1 year, >50% of cases are caused by serogroup B, for which no vaccine is licensed or available in the United States (*13,14*). Of all cases of meningococcal disease among persons aged ≥11 years, 75% are caused by serogroups (C, Y, or W-135), which are included in vaccines available in the United States (CDC, unpublished data, 2004).

Persons who have deficiencies in the terminal common complement pathway (C3, C5–9) (*15,16*) and those with anatomic or functional asplenia (*17*) are at increased risk for acquiring meningococcal disease. Antecedent viral infection, household crowding, chronic underlying illness, and both active and passive smoking also are associated with increased risk for meningococcal disease (*18–25*). During outbreaks, bar or nightclub patronage and alcohol use also have been associated with higher risk for meningococcal disease (*26–28*).

In the United States, blacks and persons of low socioeconomic status (SES) have been consistently at higher risk for meningococcal disease (*12,13*). However, race and low SES are likely risk markers rather than risk factors for this disease. A multistate case-control study in which controls were matched to case-patients by age group indicated that in a multivariable analysis (controlling for sex and education), active and passive smoking, recent respiratory illness, corticosteroid use, new residence, new school, Medicaid insurance, and household crowding all were associated with increased risk for meningococcal disease, whereas income and race were not (*18*). Additional research is needed to identify groups at risk that might benefit from prevention efforts.

Meningococcal Disease and College Students

Multiple studies have been conducted in the United States (*29–31*) and the United Kingdom (*32,33*) concerning the risk for meningococcal disease among college students. The risk for meningococcal disease among U.S. college students was higher for those who resided in dormitories than for those residing in other types of accommodations. Overall incidence among college students usually is similar to or somewhat lower than that observed among persons in the general population of similar age.

The earliest of these studies (conducted during the 1990–91 and 1991–92 academic years) had a poor response rate (38%) and indicated a low overall incidence of meningococcal disease among U.S. college students (1.0/100,000 population/year) (*31*). Cases of meningococcal disease occurred 9–23 times more frequently among students living in dormitories than among those living in other types of accommoda-

FIGURE 1. Rate* of meningococcal disease, by age — United States, 1991–2002

Source: Active Bacterial Core surveillance data.
* Per 100,000 population.

tions. A retrospective cohort study conducted in Maryland during 1992–1997 (*30*) indicated that the overall incidence of meningococcal disease among college students was similar to that among the U.S. population of persons the same age (1.7/100,000 and 1.4/100,000, respectively); however, rates of disease among students living in dormitories were higher than rates among students living off campus (3.2/100,000 and 1.0/100,000, respectively; p = 0.05).

U.S. surveillance data from the 1998–99 school year (*29*) indicated that the overall rate of meningococcal disease among undergraduate college students was lower than the rate among persons aged 18–23 years who were not enrolled in college (0.7 and 1.4/100,000, respectively) (Table 1). Rates were somewhat higher among freshmen (1.9/100,000). Among the approximately 600,000 freshmen living in dormitories, rates were higher (5.1/100,000) than among any age group in the population other than children aged <2 years but lower than the threshold (10/100,000) recommended for initiating meningococcal vaccination campaigns (*4*). In a case-control study involving 50 cases detected among college students (*29*), multivariate analysis indicated that freshmen living in dormitories were at higher risk for meningococcal disease than other students (matched odds ratio [OR]: 3.6; 95% confidence interval [CI] = 1.6–8.5).

In the United Kingdom, rates of meningococcal disease were higher among university students than among nonstudents of similar age (*32*). Regression analysis indicated that the main risk factor was catered hall accommodations (the U.K. equivalent of U.S. dormitories). A recent study conducted in the United Kingdom demonstrated a rapid increase in carriage rates of meningococci among university students in the first week of the fall semester, although rates of disease peaked later

in the academic year (*33*). The increased rate of disease among university students has prompted the United Kingdom to initiate routine vaccination of incoming university students with a bivalent A/C polysaccharide vaccine as part of a new vaccination program (*34*).

In 2000, ACIP and the Committee on Infectious Diseases of the American Academy of Pediatrics (AAP) concluded that college students, especially those living in dormitories, are at moderately increased risk for meningococcal disease compared with other persons their age (*5*). ACIP and AAP recommended that 1) college students and their parents be informed by health-care providers of the risks of meningococcal disease and of the potential benefits of vaccination with MPSV4; 2) college and university health services facilitate implementation of educational programs about meningococcal disease and the availability of vaccination services; and 3) MPSV4 be made available to those persons requesting vaccination. As of November 2004, a total of 31 states had adopted legislation requiring colleges to provide information on risks of meningococcal disease either to matriculating students or to students residing on campus, and 10 states had mandated vaccination for certain students, unless a vaccination waiver is provided (Figure 2) (*35*).

In 2004, the American College Health Association conducted an Internet-based survey of college policies and practices related to meningococcal vaccination (*36*). Of the 72 (10%) contacted colleges and universities that responded, 60% reported having a written policy on meningococcal vaccination, and 80% reported conducting some type of outreach awareness program among college students or their parents. Median vaccination rates reported for the 2002–03 and 2003–04 academic years were 20% and 35%, respectively;

TABLE 1. Number of cases and rates of meningococcal disease — United States, September 1998–August 1999*

	No. of cases	Population	Rate*
All persons aged 18–23 years	304	22,070,535[†]	1.4
Nonstudents aged 18–23 years	211	14,579,322[†§]	1.4
All college and university students	96	14,897,268[§]	0.6
Undergraduates	93	12,771,228[§]	0.7
Freshmen[¶]	44	2,285,001[§]	1.9
Dormitory residents	48	2,085,618[§**]	2.3
Freshmen[§] living in dormitories	30	591,587[§**]	5.1

Source: Bruce MG, Rosenstein NE, Capparelle JM, Shutt KA, Perkins BA, Collins M. Risk factors for meningococcal disease in college students. JAMA 2001;286:688–93.

* Per 100,000 population.

[†] 1998 census data.

[§] **Source:** National Center for Education Statistics, U.S. Department of Education, 1996–1997.

[¶] Students enrolled for the first time in any postsecondary educational institution.

** **Source:** National College Health Risk Behavior Survey (NCHRBS) — United States, 1995.

FIGURE 2. States with legislation requiring colleges to provide information on risks of meningococcal disease (Group 1) and states with mandated vaccination for certain students (Group 2)

Group 1 status
Groups 1 and 2 status

67% reported an increase in vaccination rates during the previous 3 years. On the basis of the number of vaccine doses sold, during the 2004–05 academic year, approximately 1.1 million college students received MPSV4 before arrival on campus, and an estimated 50,000–100,000 students received vaccine after arrival on campus (Sanofi Pasteur, Inc., unpublished data, 2004).

Evaluation and Management of Suspected Outbreaks of Meningococcal Disease

Since the early 1990s, outbreaks of meningococcal disease have occurred with increasing frequency in the United States. During July 1994–June 2002, a total of 76 outbreaks were identified (annual median: 10; range: 4–16) (*11*), including 48 (63%) outbreaks caused by serogroup C, 19 (25%) by serogroup B, and nine (12%) by serogroup Y. These outbreaks occurred in 32 states and involved 247 patients (accounting for <2% of total cases of meningococcal disease in the United States during this period). Of the 76 outbreaks, 26 (34%) were community-based and accounted for 53% of all outbreak-related cases. Of the 50 (65%) outbreaks that were organization-based, 13 (26%) occurred in colleges; 19 (38%) in primary and secondary schools; and nine (18%) in nursing homes. Vaccination campaigns (using an average of 2,500 doses of MPSV4 per outbreak) were conducted in 34 outbreaks (30 of which were caused by serogroup C and four by serogroup Y) (*11*).

The decision to implement a mass vaccination campaign to prevent meningococcal disease depends on whether the occurrence of more than one case represents an outbreak or an unusual clustering of endemic disease. Because the number of cases in outbreaks is usually not substantial, this determination often requires evaluation and analysis of the patterns of disease occurrence. Mass vaccination campaigns are expensive, require a massive public health effort, and can create unwarranted concern among the public. Detailed information on evaluation and management of suspected outbreaks has been published previously (*4*) and is presented in this report.

Case Definitions

The following case definitions are used in this report:
- **Confirmed case.** A confirmed case of meningococcal disease is one that is defined by isolation of *N. meningitdis* from a normally sterile site (e.g., blood or cerebrospinal fluid) from a person with clinically compatible illness.
- **Probable case.** A probable case of meningococcal disease is one that is defined by detection of polysaccharide antigen in cerebrospinal fluid (e.g., by latex agglutination, polymerase chain reaction, or immunohistochemistry) or the presence of clinical purpura fulminans in the absence of diagnostic culture from a person with clinically compatible illness (*37*).
- **Primary case.** A primary case of meningococcal disease is one that occurs in the absence of previous known close contact with another patient.
- **Secondary case.** A secondary case of meningococcal disease is one that occurs among close contacts of a primary patient >24 hours after onset of illness in the primary patient.
- **Co-primary cases.** Co-primary cases are two or more cases that occur among a group of close contacts with onset of illness separated by <24 hours.
- **Close contacts.** Close contacts of a patient who has meningococcal disease include 1) household members; 2) child-care center contacts; and 3) persons directly exposed to the patient's oral secretions (e.g., by kissing, mouth-to-mouth resuscitation, endotracheal intubation, or endotracheal tube management).

Organization- and Community-Based Outbreaks

An outbreak usually is classified as organization-based if it involves the occurrence of three or more confirmed or probable cases of meningococcal disease of the same serogroup in <3 months among persons who have a common affiliation but no close contact with each other, resulting in primary disease attack rate of >10 cases/100,000 persons. Calculation of attack rates for organization-based outbreaks is most useful for large organizations (e.g., universities). However, in the majority of organization-based outbreaks with three or even two cases of disease, the rate will be >10 cases/100,000 population. In such situations, public health officials also might consider vaccination after only two primary cases are identified.

An outbreak is classified as community-based if it involves the occurrence of three or more confirmed or probable cases of meningococcal disease in <3 months among persons residing in the same area who are not close contacts of each other and who do not share a common affiliation, with a primary disease attack rate of >10 cases/100,000 persons. Distinguishing whether an outbreak should be classified as organization- or community-based is complicated by the fact that, in certain instances, these types of outbreaks occur simultaneously.

Population at Risk

In addition to close contacts, persons considered to be at increased risk for meningococcal disease compared with historical rates of disease in the same population in the general U.S. population are classified as being at risk. The population at risk is used as the denominator in calculations of the disease attack rate. The population at risk is usually defined on the basis of organizational affiliation or community of residence. In organization-based outbreaks, cases are linked by a common affiliation other than a shared, geographically delineated community; the population at risk is thus usually the group of persons who best represent that affiliation. For example, if the only association between patients is attending the same school or university, the population at risk is all persons attending the school or university. In community-based outbreaks, patients have no common affiliation other than a shared, geographically defined community. The population at risk can be defined as the smallest geographically contiguous population that includes all (or nearly all) patients. This population is usually a neighborhood, town, city, or county, whose size is obtained from census data.

Attack Rate and Decision To Vaccinate

For a primary attack rate to be calculated, all confirmed cases of the same serogroup should be summed; secondary cases should be excluded and each set of co-primary cases counted as one case. Because attack rates are calculated both to characterize the risk for disease among the general population and to determine whether overall rates have increased, related cases (secondary and co-primary) should not be included. From an epidemiologic perspective, secondary and co-primary cases can be considered as representing single episodes of disease with direct spread to one or more close contact(s), which is consistent with endemic disease.

If three or more cases have occurred in either an organization- or a community-based outbreak during ≤3 months (starting at the time of the first confirmed or probable case), a primary attack rate should be calculated. Because of the limited number of cases typically involved and the seasonal patterns of meningococcal disease (more cases occur during fall than other times of the year), rate calculations should not be annualized. The following formula is used to calculate attack rates:

Attack rate per 100,000 = [(number of primary confirmed or probable cases during a 3-month period) / (number of population at risk)] x 100,000

Vaccination of the population at risk should be considered if the attack rate is >10 cases/100,000 persons. The actual attack rate at which the decision to vaccinate is made varies.

Public health personnel should consider the following factors: 1) completeness of case reporting and number of possible cases of meningococcal disease for which bacteriologic confirmation or serogroup data are not available; 2) occurrence of additional cases of meningococcal disease after recognition of a suspected outbreak (e.g., if the outbreak occurred 2 months previously and if no additional cases have occurred, in which case vaccination might be unlikely to prevent additional cases of meningococcal disease); and 3) logistic and financial considerations. Because available vaccines are not effective against *N. meningitdis* serogroup B, vaccination should not be considered during serogroup B outbreaks.

Vaccination Group

Those persons designated to be administered vaccine during a vaccination campaign comprise a vaccination group. The vaccination group usually includes either the whole or a subset of the population of risk. Because meningococcal disease outbreak cases occur predominantly among persons aged <30 years (*10,11*), and available vaccines are not recommended among children aged <2 years, the vaccination group usually is that portion of the population at risk aged 2–29 years.

In the majority of organization-based outbreaks, the vaccination group includes the whole population at risk, provided that all persons are aged ≥2 years. If a substantial proportion of patients are aged <2 years and thus are not eligible to receive vaccine, patients aged <2 years should be excluded, and, if at least three patients remain, the attack rate should be recalculated. If the recalculated attack rate remains >10 cases/100,000 persons, vaccination should be considered for part or all of the population at risk aged ≥2 years. In certain organization-based outbreaks, a vaccination group larger than the population at risk might be designated. For example, in a high school in which all outbreak-associated cases occurred among students, authorities might decide to offer vaccine to staff. In community-based outbreaks, the vaccination group usually can be defined as a subset of the population at risk (e.g., persons aged 2–29 years). If a substantial proportion of patients are aged ≤2 years, these patients might be excluded from calculation of an attack rate. In rare situations (e.g., in a town with a limited population) in which multiple cases have occurred among adults aged >29 years, the entire population aged ≥2 years might be considered for vaccination. For more substantial populations, this decision would be costly in terms of finances and human resources, and restricting the vaccination group to the persons in age groups with the highest attack rates might be more appropriate. Age-specific attack rates can be calculated by using the formula previously provided and by restricting the numerator and denominator to

persons within specific age groups (e.g., persons aged 2–29 years).

Genotyping of *N. meningitdis* Isolates

Genotyping of *N. meningitdis* isolates by using such methods as pulsed-field gel electrophoresis or ribotyping might provide useful information for determining whether a group of cases represents an outbreak (*38*). Outbreaks of meningococcal disease usually are caused by closely related strains. Genotyping data can allow identification of an outbreak strain and help to better define the extent of the outbreak. If strains from a group of patients are unrelated by genotyping, the group of cases most likely does not represent an outbreak. Because molecular subtyping testing might not be readily available or accessible, initiation of outbreak-control efforts should not be delayed until genotyping results are available.

Other Control Measures

Mass chemoprophylaxis (i.e., administration of antibiotics to substantial populations) is not recommended to control large outbreaks of disease. Disadvantages of mass chemoprophylaxis include cost of the drug and administration, difficulty of ensuring simultaneous administration of drugs to substantial populations, drug side effects, and emergence of resistant organisms. In addition, multiple sources and prolonged risk for exposure make this approach impractical and unlikely to succeed. In the majority of outbreak settings, these disadvantages outweigh the possible benefit in disease prevention. However, in outbreaks involving limited populations (e.g., an outbreak in a single school), administration of chemoprophylaxis might be considered (*39*), especially in serogroup B outbreaks, for which available vaccines are not effective (*40*). When making a decision about initiating mass chemoprophylaxis in these settings, public health officials should consider not only the potential for prevention of new cases but also the logistics, cost, and potential for developing antimicrobial resistance (*39,41*). If mass chemoprophylaxis is undertaken, it should be administered to all targeted persons at the same time. In the United States, measures that have not been recommended for control of meningococcal disease outbreaks include restricting travel to areas with an outbreak, closing schools or universities, or canceling sporting or social events.

Educating communities, physicians, and other health-care workers about meningococcal disease to promote an early case recognition and early care-seeking behaviors is an important part of managing suspected meningococcal disease outbreaks. Education efforts should be initiated as soon as an outbreak

of meningococcal disease is suspected (*4*). Information about the signs and symptoms of meningococcal disease is available at http://www.cdc.gov/ncidod/dbmd/diseaseinfo/ meningococcal_g.htm.

Meningococcal Tetravalent Polysaccharide Vaccine

Vaccine Composition

MPSV4 is a tetravalent meningococcal polysaccharide vaccine (Menomune-A,C,Y,W-135, manufactured by Sanofi Pasteur, Inc., Swiftwater, Pennsylvania) available in the United States (*42*). Each dose consists of the four (A, C, Y, W-135) purified bacterial capsular polysaccharides (50 μg each). MPSV4 (Menomune) is available in single-dose (0.5-mL) and 10-dose (5-mL) vials; 50-dose vials are no longer available.

Vaccine Immunogenicity and Efficacy

The immunogenicity and clinical efficacy of the serogroups A and C meningococcal vaccines have been well established. The serogroup A polysaccharide induces antibody response among certain children as young as age 3 months, although a response comparable with that occurring in adults is not achieved until age 4–5 years; the serogroup C component is poorly immunogenic among recipients aged <18–24 months (*43,44*). The serogroups A and C vaccines have demonstrated estimated clinical efficacies of ≥85% among school-aged children and adults and are useful in controlling outbreaks (*45–49*). Serogroups Y and W-135 polysaccharides are safe and immunogenic among adults and children aged >2 years (*50–52*); although clinical protection has not been documented, vaccination with these polysaccharides induces production of bactericidal antibodies. The antibody responses to each of the four polysaccharides in the tetravalent vaccine are serogroup specific and independent.

Persons whose spleens have been removed because of trauma or nonlymphoid tumors and persons who have inherited complement deficiencies have acceptable antibody responses to polysaccharide meningococcal vaccine (*53–55*). A 2003 study indicated that tetravalent polysaccharide vaccine substantially reduced the incidence of invasive meningococcal disease among patients with terminal complement deficiency compared with similar patients who were unvaccinated (*16*).

Reduced clinical efficacy has not been demonstrated among persons who have received multiple doses of vaccine. However, recent serologic studies have reported that multiple doses of serogroup A and C polysaccharide vaccine might cause immunologic hyporesponsiveness (i.e., a reduced antibody

response after subsequent challenge with the same polysaccharide antigen) to group A (*56,57*) and C (*58,59*) polysaccharide. The clinical relevance of such hyporesponsiveness is unclear.

Duration of Protection

Among infants and children aged <5 years, measurable levels of antibodies against group A and C polysaccharides decreased substantially during the first 3 years after a single dose of vaccine; among healthy adults, antibody levels also decreased, but antibodies were still detectable ≤10 years after vaccine administration (*43,60–63*). Similarly, although vaccine-induced clinical protection likely persists among school-aged children and adults for ≥3 years, the efficacy of the group A vaccine among children aged <5 years might decrease markedly within this period. In one study, efficacy among children aged <4 years at the time of vaccination declined from >90% to <10% within 3 years after vaccination; efficacy was 67% among children who were aged ≥4 years when vaccinated (*64*).

Precautions and Contraindications

Meningococcal polysaccharide vaccines have been used extensively in mass vaccination programs as well as in the military and among international travelers. Adverse reactions to polysaccharide meningococcal vaccines are usually mild; the most frequent reaction is pain and redness at the injection site, lasting for 1–2 days. Estimates of the incidence of such local reactions have varied (range: 4%–56%) (*65,66*). In certain studies, transient fever occurred among ≤5% of persons vaccinated, more commonly among infants (*44,67*).

Severe reactions to polysaccharide meningococcal vaccine are uncommon (*44,52,65–71*). The majority of studies report the rate of systemic allergic reactions (e.g., urticaria, wheezing, and rash) as 0–0.1/100,000 vaccine doses (*44,71*). Anaphylaxis has been documented among <0.1/100,000 vaccine recipients (*42,70*). Neurologic reactions (e.g., seizures, anesthesias, and paresthesias) have also been observed infrequently (*65,70*).

Meningococcal Conjugate Vaccines

Advantages of Meningococcal Conjugate Vaccines

Bacterial polysaccharides, including those comprising the capsule of *N. meningitdis*, are T-cell–independent antigens. T-cell–independent antigens do not elicit a memory response; they stimulate mature B-lymphocytes but not T-lymphocytes,

thus inducing a response that is neither long-lasting nor characterized by an anamnestic response after subsequent challenge with the same polysaccharide antigen (*72*). Thus, meningococcal polysaccharide vaccines have inherent limitations. The serogroup C polysaccharide is poorly immunogenic among children aged <2 years (*73–75*). The A polysaccharide induces antibody response in infants, but vaccine efficacy declines rapidly (*64*). Meningococcal polysaccharide vaccines do not confer long-lasting immunity (*61,64*); they also do not cause a sustainable reduction of nasopharyngeal carriage of *N. meningitdis* (*76,77*) and therefore do not substantially interrupt transmission to elicit herd immunity. Finally, multiple doses of serogroup A and C polysaccharide vaccine might cause immunologic hyporesponsiveness to the group A (*56,57*) and C (*58,59*) polysaccharide, although clinical implications of this phenomenon are unknown.

Conjugation (i.e., covalent coupling) of polysaccharide to a protein carrier that contains T-cell epitopes changes the nature of immune response to polysaccharide from T-cell–independent to T-cell–dependent, leading to a substantial primary response among infants and a strong anamnestic response at re-exposure (*78*). Both conjugate Hib and conjugate *S. pneumoniae* vaccines (introduced for mass infant immunization in the United States in 1990 and 2000, respectively) have reduced incidence of disease caused by vaccine-preventable serotypes (*1,79*). In addition, both vaccines reduce asymptomatic carriage of respective bacteria (*80–82*), thus protecting unvaccinated persons through a herd immunity effect (*1*).

Meningococcal Serogroup C Conjugate Vaccine in the United Kingdom

In November 1999, monovalent serogroup C conjugate vaccines were introduced in the United Kingdom. The national vaccination campaign introduced a routine 3-dose infant vaccination series and implemented a mass catch-up campaign during 1999–2000 targeting all persons aged 12 months–17 years (*34*). The three serogroup C conjugate vaccines used in the United Kingdom are Meningtec™ (Wyeth Lederle Vaccines and Pediatrics, Pearl River, New York); Menjugate™ (Chiron Vaccines, Siena, Italy); and NeisVac™ (Baxter Hyland Immuno, Beltsville, Maryland). Two vaccines (Meningtec and Menjugate) contain short-chain oligosaccharide (O-acetylated) derived from serogroup C capsular polysaccharide, conjugated to CRM197, a nontoxic mutant diphtheria toxin. The third vaccine (NeisVac) contains serogroup C polysaccharide (de-O-acetylated) conjugated to tetanus toxoid (*83,84*). The serogroup C conjugate meningococcal vaccines used in this campaign were licensed on the

basis of data on safety and immunogenicity but without data on clinical efficacy (*85*).

By 2001–2002, vaccine coverage in the United Kingdom was estimated as 80% among infants, 84% among toddlers, 76% among preschoolers, and 86%–87% among schoolchildren (*86*). Effectiveness of the vaccine within the first year of vaccination ranged from 88% to 98% among different age groups (*87–89*). Insufficient data are available to differentiate efficacy of the three meningococcal conjugate vaccines. Because the vaccine campaign was initiated only in 1999, long-term data on duration of protection are not yet available. However, among infants who received 3 doses of vaccine at ages 2, 3, and 4 months, efficacy declined to -81% (95% CI = -7,430–71) after only 1 year (*88*). Although the number of cases remains low, likely in part as a result of vaccine-induced herd immunity, this study raises questions about the meningococcal vaccine schedule and the need for a booster dose.

During 1999–2000, carriage rates of group C meningococci in the United Kingdom declined 66% (*90*). In addition, incidence of meningococcal serogroup C disease declined 67% among unvaccinated persons aged 1–17 years and 35% among persons aged >25 years who were not targeted for vaccination, indicating the additional vaccine benefit of eliciting herd immunity (*86*).

Meningococcal Tetravalent Conjugate Vaccine

Vaccine Composition

MCV4 is a tetravalent meningococcal conjugate vaccine (Menactra, manufactured by Sanofi Pasteur, Inc., Swiftwater, Pennsylvania) that was licensed for use in the United States in January 2005. A 0.5-mL single dose of vaccine contains 4 μg each of capsular polysaccharide from serogroups A, C, Y, and W-135 conjugated to 48 μg of diphtheria toxoid. MCV4 is available only in single-dose vials.

Immunologic Correlates of Protection

Studies among U.S. military recruits conducted in the 1960s indicated that the absence of naturally acquired bactericidal antibodies, measured by a serum bactericidal antibody assay (SBA) using an intrinsic human complement source, was associated with susceptibility to meningococcal group C disease. SBA titers $\geq$4 using human serum as an exogenous complement source (hSBA) are considered the standard correlate of clinical protection against serogroup C meningococcal disease (*91*).

Serogroup C conjugate meningococcal vaccines were licensed in the United Kingdom on the basis of data on safety and immunogenicity, without data on clinical efficacy (*85*). The immunologic data supporting the use of conjugate serogroup C vaccines were generated by serum bactericidal assay by using baby rabbit complement (rSBA). The threshold values were validated by comparing rSBA titers with those obtained by using hSBA (*85,92*). For licensure in the United Kingdom, rSBA titers of $\geq$128 were considered to predict protection; however, only 60% of rSBA titers in the range of 8–64 had hSBA titers of $\geq$4. For rSBA titers in this equivocal range, a fourfold rise in titers pre- to postvaccination was also proposed as a correlate of protection (*92*).

Further evaluation of these threshold values was performed by using vaccine efficacy estimates from postlicensure surveillance, which indicated that these threshold values provided a conservative estimate of short-term clinical efficacy; rSBA threshold of $\geq$128 underestimated efficacy, with rSBA cutoffs of $\geq$4–$\geq$8 at 4 weeks after vaccination being most consistent with observed clinical efficacy (*93*). On the basis of these efficacy estimates, the proportion of responders in multiple clinical trials of meningococcal C conjugate vaccines, and the group C seroprevalence study conducted before introduction of group C conjugate vaccines (*94*), rSBA titers of <8 have been proposed to be predictive of susceptibility to invasive meningococcal disease, and rSBA titers of $\geq$8 have been proposed to correlate with short-term protection (*95*). Limited or no similar data exist to link immune response with clinical efficacy for serogroups A, Y, or W-135.

In 1981, MPSV4 (Menomune) was licensed in the United States on the basis of data on safety and immunogenicity. Immunogenicity of this vaccine was compared with that of the vaccine then licensed for use in the United States, A/C meningococcal polysaccharide vaccine, which had demonstrated 97% efficacy against serogroup A and 90% efficacy against serogroup C (*96*). The immunologic criterion used for licensing was a fourfold or greater rise in SBA among 90% of adults at 3–4 weeks after vaccination. As a result, in 2005, MCV4 (Menactra) was licensed on the basis of findings indicating that it was not inferior to MPSV4 in terms of immunogenicity and safety (i.e., demonstrated noninferiority). A primary criterion in determining immunogenic noninferiority of the new vaccine was the percentage of vaccinees having a fourfold or greater increase in bactericidal antibody for MCV4 compared with MPSV4.

Immunogenicity

Immunogenicity Among Persons Aged 11–18 Years

A randomized controlled trial conducted among persons aged 11–18 years compared immunogenicity of MCV4 with that of MPSV4 at 28 days after vaccination. A similar percentage of subjects achieved at least a fourfold rise in rSBA titers in MCV4 and MPSV groups (Table 2). The percentage of subjects with at least a fourfold rise in rSBA was highest for serogroup W-135 (96.7% in MCV4 group and 95.3% in MPSV4 group), and lowest for serogroup Y (81.8% and 80.1%, respectively). The percentage of subjects achieving an rSBA geometric mean titer (GMT) of ≥128 was high (>98% for all serogroups) in both MCV4 and MPSV4 groups (97,98).

Immunogenicity Among Persons Aged 18–55 Years

Another randomized controlled trial conducted among persons aged 18–55 years compared immunogenicity of MCV4 and that of MPSV4 at 28 days after vaccination. Although the percentage of subjects achieving at least a fourfold increase in rSBA titer for each serogroup was higher in the MPSV4 group than in the MCV4 group (Table 2), the criteria for demonstrating immunologic noninferiority to MPSV4 were still achieved. As was the case among persons aged 11–18 years, this percentage was highest for serogroup W-135 (89.4% in the MCV4 group and 94.4% in the MPSV4 group) and lowest for serogroup Y (73.5% and 79.4%, respectively). The percentage of subjects achieving an rSBA GMT of ≥128 was high (>97% for all serogroups) in both MCV4 and MPSV4 groups (97,98).

Persistence of Antibodies After 3 Years and Response to Revaccination

MCV4 was administered to 76 subjects previously vaccinated with MCV4, 77 subjects previously vaccinated with MPSV4, and 88 age-matched vaccine-naïve subjects (97) (Sanofi Pasteur, Inc., unpublished data, 2004). Immunologic indices were measured before revaccination (day 0) and at days 8 and 28 after revaccination (Table 3).

Subjects initially vaccinated with MCV4 had higher rSBA GMT at day 0 than those vaccinated with MPSV4 (Table 3); this difference was statistically significant for serogroups A ($p<0.001$) and W-135 ($p<0.001$). In addition, a higher percentage of those initially vaccinated with MCV4 had rSBA titers of ≥128 than those initially vaccinated with MPSV4 (Table 3). Vaccine-naïve subjects had lower rSBA on day 0 than subjects previously vaccinated with either MCV4 or MPSV4.

Response to revaccination with MCV4 was assessed by administering MCV4 to subjects previously vaccinated with MPSV4 or MCV4 and to vaccine-naïve control subjects. All subjects in all three groups achieved rSBA titers of ≥128 at both 8 and 28 days after receiving MCV4 (Table 3). Subjects initially primed with MCV4 achieved higher rSBA GMTs than naïve control subjects for all serogroups except A. In contrast, rSBA GMTs of those primed with MPSV4 were lower than those of vaccine-naïve control subjects on both days 8 and 28 for all serogroups (Table 3).

TABLE 2. Percentage of subjects achieving a fourfold rise or greater in serum bactericidal activity by using baby rabbit complement (rSBA), rSBA geometric mean titer (GMT) of ≥128, and rSBA GMT, 28 days after vaccination with meningococcal conjugate vaccine (MCV4) and meningococcal polysaccharide vaccine (MPSV4)

| | Fourfold or greater increase in rSBA titer | | | | rSBA GMT | | rSBA GMT ≥128 | |
| | MCV4 | | MPSV4 | | MCV4 | MPSV4 | MCV4 | MPSV4 |
Age group, serogroup	%	(95% CI*)	%	(95% CI)	GMT	GMT	%	%
Persons aged 11–18 yrs†								
A	92.7	(89.8–95.0)	92.4	(89.5–94.8)	5,483	3,246	99.8	100.0
C	91.7	(88.7–94.2)	88.7	(85.2–91.5)	1,924	1,639	98.8	98.4
Y	81.8	(77.8–85.4)	80.1	(76.0–83.8)	1,322	1,228	99.5	99.3
W-135	96.7	(94.5–98.2)	95.3	(92.8–97.1)	1,407	1,545	98.6	98.8
Persons aged 18–55 yrs§								
A	80.5	(78.2–82.6)	84.6	(82.3–86.7)	3,897	4,114	99.8	99.9
C	88.5	(86.6–90.2)	89.7	(87.8–91.4)	3,231	3,469	98.8	98.5
Y	73.5	(71.0–75.9)	79.4	(76.9–81.8)	1,750	2,449	97.0	98.5
W-135	89.4	(87.6–91.0)	94.4	(92.8–95.6)	1,271	1,871	97.1	98.5

Sources: Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee, September 22, 2004: briefing information. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration; 2004. Available at http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4072b1.htm; Food and Drug Administration. Product approval information—licensing action. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; 2005. Available at http://www.fda.gov/cber/products/mpdtave011405.htm.
* Confidence interval.
† N = 423 in MCV4 group; 423 in MPSV4 group.
§ N = 1,280 in MCV4 group; 1,098 in MPSV4 group.

TABLE 3. Geometric mean titer (GMT) of serum bactericidal activity by using baby rabbit complement (rSBA) and percentage of subjects aged 14–21 years achieving rSBA GMT of ≥128 before (day 0) and at days 8 and 28 after revaccination with meningococcal conjugate vaccine (MCV4) at 3 years after previous vaccination in three groups (primed with MCV4, primed with meningococcal polysaccharide vaccine [MPSV4], and vaccine-naïve)

	Day 0, rSBA GMT			Day 8, rSBA GMT			Day 28, rSBA GMT		
Indicator, serogroup	Primed with MCV4 (n = 76)	Primed with MPSV4 (n = 77)	Vaccine-naïve (n = 88)	Primed with MCV4 (n = 76)	Primed with MPSV4 (n = 77)	Vaccine-naïve (n = 88)	Primed with MCV4 (n = 76)	Primed with MPSV4 (n = 77)	Vaccine-naïve (n = 88)
GMT									
A	1,082	171	84	9,393	4,406	12,936	4,326	3,271	6,399
C	211	109	43	18,113	1,196	7,453	8,192	665	2,955
Y	592	380	211	12,808	2,896	7,053	5,846	2,327	4,366
W-135	447	120	22	9,566	1,921	5,657	4,612	1,578	2,955
% GMT ≥128									
A	94.7	70.1	58.0	100.0	100.0	100.0	100.0	100.0	100.0
C	71.1	57.1	45.5	100.0	92.1	98.9	100.0	100.0	100.0
Y	96.1	83.1	74.7	100.0	97.4	100.0	100.0	100.0	100.0
W-135	83.1	67.5	28.4	100.0	100.0	100.0	100.0	100.0	100.0

Sources: Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee, September 22, 2004: briefing information. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration; 2004. Available at http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4072b1.htm; Sanofi Pasteur, Inc., unpublished data, 2004.

Concomitant Administration of MCV and Other Vaccines

The concomitant administration of MCV4 and tetanus and diphtheria toxoids adsorbed for adult use (Td, manufactured by Sanofi Pasteur, Inc., Swiftwater, Pennsylvania) was evaluated in a double-blind, controlled trial of participants aged 11–17 years. One group received Td and MCV4 concomitantly at separate injection sites, followed by a saline placebo 28 days later; the other group received Td and a saline placebo at separate injection sites, followed 28 days later by MCV4. Concomitant administration of Td and MCV4 did not adversely affect immune response to either vaccine (97,98).

When MCV4 and Td were administered concomitantly, antibody response to diphtheria antigen 28 days after vaccination was greater (diphtheria GMT 120.9 IU/mL) than when Td and MCV4 were administered sequentially, Td first (diphtheria GMT 8.4 IU/mL 28 days after Td dose) followed by MCV4 28 days after Td (diphtheria GMT 16.9 IU/mL 28 days after MCV4 dose) (97). The prelicensure data demonstrated comparable overall safety profiles among adolescents who received simultaneous and sequential vaccination (Td followed by MCV4 28 days later). The immunological and safety profiles among adolescents receiving MCV4 followed by Td on a later date were not evaluated during prelicensure trials (see "Safety of Concomitant Administration of MCV4 and Other Vaccines").

Among adults aged 18–55 years, a randomized controlled trial assessed immunogenicity of MCV4 and typhoid vaccine 1) when MCV4 and typhoid vaccine were administered concomitantly and 2) when typhoid vaccine was administered concomitantly with placebo and MCV4 was administered 28 days later. Concomitant administration did not adversely affect immune response to either typhoid vaccine or MCV4 (97,98).

Safety

Systemic and Local Adverse Reactions

Among persons aged 11–18 years, safety of MCV4 and MPSV4 was assessed in two randomized controlled trials (97,98). The percentage of subjects reporting systemic adverse events was similar for persons who received either vaccine. In one study, approximately half of the participants experienced at least one systemic adverse reaction, and <5% experienced at least one severe systemic reaction. Fever (i.e., temperature ≥100°F [≥38°C]) was reported by 5.1% of those who received MCV4 and by 3.0% of those who received MPSV4 (Table 4).

Among persons aged 18–55 years, the safety of MCV4 and of MPSV4 also were compared in two randomized controlled trials. The percentage of subjects reporting systemic adverse events was similar for persons who received either vaccine. In one study, 62% of participants experienced at least one systemic adverse reaction, and <4% experienced severe systemic reaction after receiving MCV4. Fever was reported by 1.5% of those who received MCV4 and by 0.5% of those who received MPSV4 (Table 4).

Local adverse reactions were more common among those persons aged 11–18 years who received MCV4 than among those who received MPSV4 (Table 5); 13% of those who

TABLE 4. Percentage of subjects aged 11–18 years and those aged 18–55 years reporting systemic adverse reactions* 0–7 days after vaccination with either meningococcal conjugate vaccine (MCV4) or meningococcal polysaccharide vaccine (MPSV4)

Reaction	Persons aged 11–18 yrs (%)		Persons aged 18–55 yrs (%)	
	MCV4 n = 2,265	MPSV4 n = 970	MCV4 n = 1,371	MPSV4 n = 1,159
Any systemic adverse reaction	55.1	48.7	61.9	60.3
Any severe[†] systemic adverse reaction	4.3	2.6	3.8	2.6
Fever				
$\geq$100.0°F ($\geq$38.0°C)	5.1[§]	3.0[§]	1.5[§]	0.5[§]
$\geq$103.1°F ($\geq$39.5°C)	0.6	0.4		
$\geq$104.0°F ($\geq$40.0°C)			0.3	0.1

Sources: Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee, September 22, 2004: briefing information. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration; 2004. Available at http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4072b1.htm. Food and Drug Administration. Product approval information—licensing action. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; 2005. Available at http://www.fda.gov/cber/products/mpdtave011405.htm. Sanofi Pasteur, Inc., unpublished data, 2004.

* Including fever, headache, fatigue, malaise, chills, arthralgia, anorexia, vomiting, diarrhea, seizures, or rash.
[†] Fever $\geq$103.1°F ($\geq$39.5°C) for persons aged 11–18 years or >104.0°F ($\geq$40.0°C) for adults aged 18–55 years; headache, fatigue, malaise, chills, or arthralgia requiring bed rest; anorexia or skipping three or more meals; three or more episodes of vomiting; five or more episodes of diarrhea; or presence of rash or seizures.
[§] Values in MCV4 and MPSV4 groups that are statistically different (p<0.05). P values were calculated by using chi-square tests.

TABLE 5. Percentage of persons aged 11–18 years and persons aged 18–55 years reporting local adverse reactions 0–7 days after vaccination with either meningococcal conjugate vaccine (MCV4) or meningococcal polysaccharide vaccine (MPSV4)

Reaction	Persons aged 11–18 yrs (%)		Persons aged 18–55 yrs (%)	
	MCV4 (n = 2,265)	MPSV4 (n = 970)	MCV4 (n = 1,371)	MPSV4 (n = 1,159)
Redness				
Any	10.9*	5.7*	14.4	16.0
1–2 inches	1.6*	0.4*	2.9	1.9
>2 inches	0.6*	0*	1.1*	0.1*
Swelling				
Any	10.8*	3.68*	12.6*	7.6*
1–2 inches	1.9*	0.3*	2.3*	0.7*
>2 inches	0.5*	0*	0.9*	0*
Induration				
Any	15.7*	5.2*	17.1*	11.0*
1–2 inches	2.5*	0.5*	3.4*	1.0*
>2 inches	0.3	0	0.7*	0*
Pain[†]				
Any	59.2*	28.7*	53.9*	48.1*
Moderate	12.8*	2.6*	11.3*	3.3*
Severe	0.3	0	0.2	0.1

Sources: Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee, September 22, 2004: briefing information. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration; 2004. Available at http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4072b1.htm. Food and Drug Administration. Product approval information—licensing action. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; 2005. Available at http://www.fda.gov/cber/products/mpdtave011405.htm. Sanofi Pasteur, Inc., unpublished data, 2004.

* Denotes values in MCV4 and MPSV4 groups that are statistically different (p<0.05). P values were calculated for each category and severity by using chi-square tests.
[†] Mild = symptoms present, but arm movement not affected; moderate = usual arm movement limited; and severe = disabling.

received MCV4 reported pain that limited movement in the arm of injection, compared with 3% of those who received MPSV4. These differences in frequency of local reactions are related to the amount of diphtheria toxoid contained in each vaccine (99). The frequency of local adverse reactions reported after MCV4 was similar to that reported after Td vaccine (97,98).

As with persons aged 11–18 years, local adverse reactions among persons aged 18–55 years were reported more commonly by those who received MCV4 than by those who received MPSV4 (Table 5). However, the frequency of local adverse reactions reported by adults after MCV4 was similar to that reported after typhoid vaccine (97,98).

Safety of Concomitant Administration of MCV4 and Other Vaccines

Among persons aged 11–17 years, frequency of reported local adverse effects at MCV4 injection site in the group for which MCV4 was administered concomitantly with Td was similar to those in which MCV4 was administered 28 days after Td. The percentage (58.6%) of subjects reporting at least one systemic adverse reaction after concomitant administration of MCV4 and Td was similar to the percentage (54.1%)

of systemic reactions reported after Td was administered concomitantly with a placebo. Among persons aged 18–55 years, the frequency of local and systemic adverse effects was similar for those receiving concomitant administration of MCV4 and typhoid vaccine and those who received MCV4 28 days after receiving typhoid vaccine (97,98).

Serious Adverse Events in All Safety Studies

A total of 5,453 subjects aged 11–55 years who received MCV4 and 2,923 subjects in the same age group who received MPSV4 completed follow-up 6 months after vaccination. Serious adverse events reported within a 6-month period after vaccination occurred at the same rate (1.3%) in the MCV4 and MPSV4 groups. The events reported were consistent with events expected among healthy adolescent and adult populations (98).

Cost-Effectiveness Analyses

Cost-Effectiveness Analysis of MPSV4 Vaccine Among College Students

From a societal perspective, the economic costs and benefits of vaccinating 1) a cohort of 591,587 freshmen who live in dormitories and 2) all freshmen enrolled in U.S. colleges, regardless of housing status (N = 2.4 million) were evaluated, on the basis of an assumption that the benefits of vaccination would last 4 years (*100*). Best- and worst-case scenarios were evaluated by varying the cost of vaccine and administration (range: $54–$88), costs per hospitalization ($10,924–$24,030), the value of premature death on the basis of lifetime productivity ($1.3 million–$4.8 million), the cost per case of vaccine side effects ($7,000–$24,540/1 million doses), and the average long-term cost of treating a case of sequelae of disease ($1,298–$14,600). Vaccination coverage (60% and 100%, respectively) and vaccine efficacy (80% and 90%, respectively) also were varied for evaluation purposes.

Vaccination of freshmen who live in dormitories would result in the administration of approximately 354,950–591,590 doses of vaccine each year, preventing 16–30 cases of meningococcal disease and one to three deaths each year. The cost per case prevented would be an estimated $617,000–$1.85 million, at a cost per death prevented of $6.8–$20.4 million and a cost per life-year saved (LYS)* of $62,042–$489,185 (*100*). Vaccination of all freshmen would result in the administration of approximately 1,364,400–2,274,000 doses of vaccine each year, preventing 37–69 cases of meningococcal disease and two to five deaths each year. The cost per case prevented would be $1.4–$2.9 million, at a cost per death prevented of $22–$48 million (*100*). These data are similar to data derived from previous studies (*101*).

Cost-Effectiveness Analysis of MCV4 Vaccine Among Adolescents Aged 11 Years

From a societal perspective, the economic costs and benefits of vaccinating a cohort of approximately 4,238,670 U.S. adolescents aged 11 years were evaluated, on the basis of an assumption that the benefits of vaccination would last 22 years

(*102*). A multivariable (Monte Carlo) analysis was performed in which multiple parameters were varied simultaneously over specified probability distributions. These parameters included disease incidence (46%–120% of the 10-year average), case-fatality ratio (34%–131% of the 10-year average), rates of long-term sequelae, acute meningococcal disease costs (i.e., inpatient care, parents' work loss, and public health response), lifetime costs of meningococcal disease sequelae, and cost of vaccine and administration (range: $64–$114). Vaccination coverage (16%–95%) and vaccine efficacy (39%–99%) also were varied for evaluation purposes.

Median program costs for vaccination of adolescents aged 11 years would be $227 million (5th–95th percentile: $158–$406 million). If a 3% discount rate were used for costs and benefits, during a 22-year period, vaccination among adolescents would prevent 270 cases and 36 deaths (21 cases and three deaths in the first year). The median cost would be $633,000 (5th–95th percentile: $329,000–$1,299,000)/case prevented; $5.0 million (5th–95th percentile: $2.4–$10.9 million)/death prevented; and $121,000 (5th–95th percentile: $69,000–$249,000)/LYS saved (*102*).

Cost-Effectiveness Analysis of a Catch-Up Vaccination Campaign with MCV4

The direct and indirect (herd immunity) benefits of a one-time catch-up vaccination campaign with MCV4 of adolescents aged 11–17 years followed by routine annual vaccination of adolescents aged 11 years were analyzed (CDC, unpublished data, 2005). For this purpose, a probabilistic model of disease burden and economic impacts was built for a 10-year period with and without an adolescent catch-up program. U.S. age- and serogroup-specific surveillance data on incidence and case fatality rates were used, as were hypothetical age-specific reductions in attack rates among unvaccinated persons obtained on the basis of U.K. data (*86,103*). Medical, work loss, and public response costs were estimated with and without a catch-up campaign, as were lifetime costs of meningococcal disease sequelae. After disease and vaccination program costs were projected, estimated costs per case averted, deaths prevented, LYS, and quality-adjusted life years (QALY)† saved were estimated.

With herd immunity effects equivalent to recent experience in the United Kingdom, catch-up vaccination of adolescents plus an added routine program would prevent 5,263 cases

---

* The number of life-years saved as a result of a preventive intervention (i.e., the number of potential years of life expected if disease-specific events leading to premature death not occur [healthy life expectancy]). The number of life-years saved will be less or at the most equal to the number of potential years lost pre-intervention. Because life expectancy is age-specific, life-years saved is often calculated as the difference between the age-specific healthy life expectancy and the age when a disease-specific event leading to premature mortality could occur without the intervention.

† A measure based on individual preferences for states of health that assigns a value of 1 to a year of perfect health and 0 to death. QALYs measure not only years of life saved but also functioning and health preserved. QALYs are highly relevant when disease-specific outcomes lead to both mortality (i.e., premature death) and substantial morbidity (i.e., temporal or permanent disability). Thus, effectiveness outcomes are expressed as change in health status.

during a 10-year period, a 32% reduction in the number of cases. Excluding program costs, the catch-up program would save $338 million in medical and public response costs and $591 million in time off from work, long-term disability, and premature death. At a hypothetical cost of $83 per vaccinee, a catch-up vaccination program (including 9 years of routine vaccination) would cost society approximately $3.6 billion (45% of this sum in the first year). At a 3% discount rate, the catch-up program would cost society $532,000/case averted, $5.9 million/death prevented, $138,000/LYS, and $64,000/QALY saved. A 20% reduction in herd immunity effects would increase the cost per LYS by $21,000; a $30 decrease in the cost of vaccination would decrease the cost per LYS by $55,000. On the basis of the assumption that herd immunity can be generated, targeting only those U.S. counties in which the disease is highly endemic would decrease the cost per LYS by two thirds.

Catch-up vaccination of adolescents can have a substantial impact on disease burden and costs. However, these data demonstrate that catch-up and routine vaccination programs with MCV4 among adolescents are more costly per health outcome than existing vaccination strategies for Hib and *S. pneumoniae* (*104,105*). Compared with routine vaccination of children aged 11 years, catch-up vaccination could cost up to 20% more/LYS.

Recommendations for Use of Meningococcal Vaccines

Routine Vaccination of Adolescents

ACIP recommends routine vaccination of young adolescents (defined in this report as persons aged 11–12 years) with MCV4 at the preadolescent health-care visit (i.e., a visit to a health-care provider at age 11–12 years, at which time ACIP and other professional organizations [e.g., AAP and the American Medical Association] recommend that persons aged 11–12 years receive appropriate vaccinations and other preventive services [*106–109*]). Introducing a recommendation for MCV4 vaccination among persons aged 11–12 years might strengthen the role of the preadolescent health-care visit and have a positive effect on vaccine coverage during adolescence. For those adolescents who have not previously received MCV4, ACIP recommends vaccination before high school entry (at approximately age 15 years) as an effective strategy to reduce meningococcal disease incidence among adolescents and young adults. By 2008, the goal will be routine vaccination with MCV4 of all adolescents beginning at age 11 years. Other adolescents who wish to decrease their risk for meningococcal disease may elect to receive vaccine.

Other Populations at Increased Risk for Meningococcal Disease

Routine vaccination also is recommended for certain persons who have increased risk for meningococcal disease (Table 6). Use of MCV4 is preferred among persons aged 11–55 years; however, use of MPSV4 is recommended among children aged 2–10 years and persons aged >55 years. If MCV4 is unavailable, MPSV4 is an acceptable alternative for persons aged 11–55 years.

The following populations are at increased risk for meningococcal disease:
- college freshmen living in dormitories (*29,30*);
- microbiologists who are routinely exposed to isolates of *N. meningitdis* (*110*);
- military recruits (*111*);
- persons who travel to or reside in countries in which *N. meningitdis* is hyperendemic or epidemic, particularly if contact with the local population will be prolonged (*112*);
- persons who have terminal complement component deficiencies (*15,16,113*); and
- persons who have anatomic or functional asplenia (*17*).

Because of feasibility constraints in targeting freshmen in dormitories, colleges can elect to target their vaccination campaigns to all matriculating freshmen. The risk for meningococcal disease among nonfreshmen college students is similar to that for the general population of similar age (age 18–24 years) (*29*). However, the vaccines are safe and immunogenic and therefore can be provided to nonfreshmen college students who want to reduce their risk for meningococcal disease.

For travelers, vaccination is especially recommended to those visiting the parts of sub-Saharan Africa known as the "meningitis belt" (*112*) during the dry season (December–June). Vaccination is required by the government of Saudi Arabia for all travelers to Mecca during the annual Hajj. Advisories for travelers to other countries will be issued when epidemics of meningococcal disease caused by vaccine-preventable serogroups are detected. Travelers' health information is available from CDC at 877-FYI-TRIP (toll-free) or at http://www.cdc.gov/travel. Further information concerning geographic areas for which vaccination is recommended can be obtained from international health clinics for travelers and state health departments.

Patients with human immunodeficiency virus (HIV) are likely at increased risk for meningococcal disease, although not to the extent that they are at risk for invasive *S. pneumoniae* infection (*20,114*). Although the efficacy of MCV4 among HIV-infected patients is unknown, HIV-infected patients may

TABLE 6. Recommendations for the use of meningococcal vaccines among persons not vaccinated previously

Population group	Age group (yrs)				
	<2	2–10	11–19	20–55	>55
General population	Not recommended	Not recommended	A single dose of MCV4* is recommended at age 11–12 years (at preadolescent assessment visit) or at high school entry (at approximately age 15 years)	Not recommended	Not recommended
Groups at increased risk College freshmen living in dormitories Certain travelers§ Certain microbiologists¶ Certain populations experiencing outbreaks of meningococcal disease** Military recruits Persons with increased susceptibility††	Not usually recommended†	A single dose of MPSV4	A single dose of MCV4 is preferred (MPSV4 is an acceptable alternative)	A single dose of MCV4 is preferred (MPSV4 is an acceptable alternative)	A single dose of MPSV4

* Meningococcal conjugate vaccine.

† Meningococcal polysaccharide vaccine (MPSV4) (2 doses, 3 months apart) can be considered for children aged 3–18 months to elicit short-term protection against serogroup A disease (a single dose should be considered for children aged 19–23 months).

§ Persons who travel to or in areas where *Neisseria meningitidis* is hyperendemic or epidemic are at increased risk of exposure, particularly if contact with the local population will be prolonged. Vaccination is especially recommended to those visiting the "meningitis belt" of sub-Saharan Africa during the dry season (December–June), and vaccination is required by the government of Saudi Arabia for all travelers to Mecca during the annual Hajj. Advisories for travelers are available at http://www.cdc.gov/travel/outbreaks.htm, http://www.cdc.gov/travel, or by calling CDC's Travelers' Health Hotline at 877-FYI-TRIP (toll-free).

¶ Microbiologists who are routinely exposed to isolates of *N. meningitidis* should be vaccinated.

** The use of vaccination in outbreak settings has been described previously (**Source:** CDC. Control and prevention of meningococcal disease, and Control and prevention of serogroup C meningococcal disease: evaluation and management of suspected outbreaks: recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 1997;46 [No. RR-5]:13–21).

†† Includes persons who have terminal complement component deficiencies and persons with anatomic or functional asplenia.

elect vaccination. For persons aged 11–55 years who have been previously vaccinated with MPSV4, revaccination with MCV4 is not indicated unless vaccination occurred 3–5 years previously and the person still remains at increased risk for meningococcal disease (see Revaccination).

Adults Aged 20–55 Years

MCV4 is licensed for use among adults aged 20–55 years. It is safe, immunogenic (*97,98,115,116*), and likely to provide relatively long-lasting protection against meningococcal disease caused by serogroups A, C, Y, and W-135. The rates of meningococcal disease are low in this age group, and vaccination will decrease but not eliminate risk. Therefore, routine vaccination is not recommended; however, persons who wish to decrease their risk for meningococcal disease may elect to be vaccinated.

Children Aged <11 Years and Adults Aged >55 Years

MCV 4 is not licensed for use among children aged <11 years or adults aged >55 years. Routine vaccination with MPSV4 is not recommended for children aged <2 years because it is relatively ineffective and offers a short duration of protection. Routine vaccination with MPSV4 is not recommended for children aged 2–10 years and adults aged >55 years who are not identified as being at increased risk for meningococcal disease.

Outbreaks of Meningococcal Disease

Both MPSV4 (*4*) and MCV4 are recommended for use in control of meningococcal outbreaks caused by vaccine-preventable serogroups (A, C, W-135, and Y) of *N. meningitidis*. An outbreak is defined by the occurrence of at least three§ confirmed or probable primary¶ cases of serogroup C meningococcal disease in ≤3 months, with a resulting primary attack rate of ≥10 cases/100,000 population. For calculation of this threshold, population-based rates are used rather than age-specific attack rates. These recommendations are based on experience with serogroup C meningococcal outbreaks, but these principles might be applicable to outbreaks caused by the other vaccine-preventable meningococcal serogroups, including Y, W-135, and A. Both MCV4 and MPSV4 can be used for outbreak control, although use of

§ Calculation of attack rates for organization-based outbreaks is most useful for sizable organizations (e.g., certain universities). However, for the majority of organization-based outbreaks with three cases of disease, the rate will be >10 cases/100,000 population. Thus, occurrence of three cases in these settings should prompt consideration of vaccination. In certain situations, public health officials also might consider vaccination after only two primary cases are identified.

¶ To calculate a primary attack rate, sum all confirmed cases; exclude secondary cases, and count each set of co-primary cases as one case. A primary case is one that occurs in the absence of previous known close contact with another patient. A secondary case is one that occurs among close contacts of a primary patient ≥24 hours after onset of illness in the primary patient. If two or more cases occur among a group of close contacts with onset of illness separated by <24 hours, these cases are considered to be co-primary.

MCV4 is preferred if the population targeted for vaccination includes age groups for which MCV4 is licensed. Detailed recommendations on evaluation and management of suspected outbreaks of meningococcal disease have been published previously (4).

Administration

For persons aged 11–55 years, MCV4 is administered intramuscularly as a single 0.5-mL dose. MPSV4 is administered subcutaneously as a single 0.5-mL dose to persons aged >2 years. MCV4 and MPSV4 can be administered concomitantly with other vaccines, but at a different anatomic site (4,117). Protective levels of antibodies are usually achieved within 7–10 days of vaccination (60,118).

Revaccination

Revaccination might be indicated for persons previously vaccinated with MPSV4 who remain at increased risk for infection (e.g., persons residing in areas in which disease is epidemic), particularly children who were first vaccinated at age <4 years. Such children should be considered for revaccination after 2–3 years if they remain at increased risk. Although the need for revaccination among adults and older children after receiving MPSV4 has not been determined, antibody levels decline rapidly after 2–3 years, and, if indications still exist for vaccination, revaccination might be considered after 5** years (4). Repeated vaccination with serogroup A and C polysaccharide vaccine might induce immunologic hyporesponsiveness (56–59), although clinical implications of such hyporesponsiveness are not known. Hyporesponsiveness to serogroup C polysaccharide can be overcome by vaccination with serogroup C conjugate vaccine (119,120). MCV4 is recommended for revaccination of persons aged 11–55 years; however, use of MSPV4 is acceptable.

ACIP expects that MCV4 will provide longer protection than MPSV4; however, studies are needed to confirm this assumption (87). More data will likely become available within the next 5 years to guide recommendations on revaccination for persons who were previously vaccinated with MCV4.

Precautions and Contraindications

Recommended vaccinations can be administered to persons with minor acute illness (e.g., diarrhea or mild upper-respiratory tract infection with or without fever) (117). Vaccination should be deferred for persons with moderate or severe acute illness until the person's condition improves. Vaccination with MCV4 or MPSV4 is contraindicated among

persons known to have a severe allergic reaction to any component of the vaccine, including dipththeria toxoid (for MCV4), or to dry natural rubber latex. Any adverse effect suspected to be associated with MCV4 or MPSV4 vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). More information about VAERS is available at 800-822-7967 (toll-free) or from http://www.vaers.org.

Because both MCV4 and MPSV4 are inactivated vaccines, they may be administered to persons who are immunosuppressed as a result of disease or medications; however, response to the vaccine might be less than optimal (117).

Studies of vaccination with MPSV4 during pregnancy have not documented adverse effects among either pregnant women or newborns (121–123). On the basis of these data, pregnancy should not preclude vaccination with MPSV4, if indicated. MCV4 is safe and immunogenic among nonpregnant persons aged 11–55 years, but no data are available on the safety of MCV4 during pregnancy. Women of childbearing age who become aware that they were pregnant at the time of MCV4 vaccination should contact their health-care provider or the vaccine manufacturer.

Future Meningococcal Vaccines, Areas for Research, and Public Education

MCV4 has been licensed on the basis of data regarding safety and short-term immunogenicity. Postmarketing studies are planned (98), including a study to evaluate the duration of the antibody response among participants who had received a single dose of MCV4 vaccine or MPSV4 vaccine 5 and 10 years earlier and a study to evaluate safety and immunogenicity when MCV4 is given concomitantly with tetanus and reduced diphtheria and acellular pertussis vaccine adsorbed (Tdap). However, immunogenicity data alone are insufficient to predict vaccine effectiveness and herd immunity effect, which depends largely on the ability of vaccine to alter transmission patterns. Additional studies are needed to evaluate vaccine effectiveness, vaccine impact on nasopharyngeal carriage of meningococci, and indirect effects of vaccine on disease rates among unvaccinated populations.

Meningococcal conjugate vaccines might be considered for licensing in the United States among persons in other age groups, including infants and children aged ≤10 years (98). These vaccines are undergoing clinical trials and are likely to have better immunogenicity among infants and young children than MPSV4 (124–126), which is the only vaccine available for these age groups in the United States. Information on vaccine effectiveness, duration of protection, and herd

---

** Certain sources recommend revaccination after 3 years (4).

immunity obtained from MCV4 evaluation studies will be valuable in guiding prevention policies and formulating recommendations for vaccination of persons in other age groups.

Because serogroup B capsular polysaccharide is poorly immunogenic in humans, vaccine development for serogroup B meningococci have focused on common proteins, including the outer membrane proteins (OMP) of specific epidemic strains. Efficacy of OMP vaccines has been demonstrated among older children and adults but not among infants and young children, in whom rates of disease are highest (127–130). In addition, the variability in OMP strains causing endemic disease will likely limit their usefulness in the United States (131,132).

Because of the potential limitations of these vaccines, other new approaches to serogroup B vaccines are being pursued, including the conjugation of a modified serogroup B polysaccharide (after substitution of the N-acetyl group with an N-propionyl group) to a recombinant serogroup B meningococcal porin protein. Although this vaccine is immunogenic in mice and nonhuman primates, concern exists that the vaccine might not be safe (132). In addition, with the recent sequencing of the serogroup B meningococcal genome, new genes encoding putative membrane proteins have been identified, indicating potential new targets for serogroup B vaccines (133–135). The availability of new meningococcal conjugate vaccines and the development of new vaccine strategies should lead to substantial improvements in global control and prevention of meningococcal disease.

Although the signs and symptoms of meningococcal disease are frequently nonspecific, increasing awareness for meningococcal disease can result in earlier medical care-seeking behavior and improved clinical outcomes. In addition, educating adolescents and their parents about the benefits of receiving MCV4 is key to preventing a substantial number of cases of meningococcal disease. Finally, educating policy makers and the general public about the benefits of receiving

MCV4 vaccine might improve vaccination coverage rates and substantially decrease the burden of meningococcal disease in the United States.

Antimicrobial Chemoprophylaxis

In the United States, the primary means for prevention of sporadic meningococcal disease is antimicrobial chemoprophylaxis of close contacts of a patient with invasive meningococcal disease (Table 7). Close contacts include 1) household members (136,137), 2) child-care center contacts (136,138), and 3) anyone directly exposed to the patient's oral secretions (e.g., through kissing, mouth-to-mouth resuscitation, endotracheal intubation, or endotracheal tube management). For travelers, antimicrobial chemoprophylaxis should be considered for any passenger who had direct contact with respiratory secretions from an index-patient or for anyone seated directly next to an index-patient on a prolonged flight (i.e., one lasting ≥8 hours). Guidelines for chemoprophylaxis of travelers have been published previously (139). The attack rate for household contacts exposed to patients who have sporadic meningococcal disease was estimated to be four cases/1,000 persons exposed, which is 500–800 times greater than the rate for the total population (137). In the United Kingdom, the attack rate among health-care workers exposed to patients with meningococcal disease was determined to be 25 times higher than among the general population (140).

Because the rate of secondary disease for close contacts is highest immediately after onset of disease in the index patient, antimicrobial chemoprophylaxis should be administered as soon as possible (ideally <24 hours after identification of the index patient). Conversely, chemoprophylaxis administered >14 days after onset of illness in the index patient is probably of limited or no value. Oropharyngeal or nasopharyngeal cultures are not helpful in determining the need for chemoprophylaxis and might unnecessarily delay institution of this preventive measure.

TABLE 7. Schedule for administering chemoprophylaxis against meningococcal disease

Drug	Age group	Dosage	Duration and route of administration*
Rifampin[†]	Children aged <1 mo	5 mg/kg body weight every 12 hrs	2 days
	Children aged ≥1 mo	10 mg/kg body weight every 12 hrs	2 days
	Adults	600 mg every 12 hrs	2 days
Ciprofloxacin[§]	Adults	500 mg	Single dose
Ceftriaxone	Children aged <15 yrs	125 mg	Single IM[¶] dose
Ceftriaxone	Adults	250 mg	Single IM dose

* Oral administration unless indicated otherwise.
[†] Not recommended for pregnant women because it is teratogenic in laboratory animals. Because the reliability of oral contraceptives might be affected by rifampin therapy, consideration should be given to using alternative contraceptive measures while rifampin is being administered.
[§] Not usually recommended for persons aged <18 years or for pregnant and lactating women because it causes cartilage damage in immature laboratory animals. Can be used for chemoprophylaxis of children when no acceptable alternative therapy is available. Recent literature review identified no reports of irreversible cartilage toxicity or age-associated adverse events among children and adolescents (**Source:** Burstein GR, Berman SM, Blumer JL, Moran JS. Ciprofloxacin for the treatment of uncomplicated gonorrhea infection in adolescents: does the benefit outweigh the risk? Clin Infect Dis 2002;35:S191–9).
[¶] Intramuscular.

Rifampin, ciprofloxacin, and ceftriaxone are 90%–95% effective in reducing nasopharyngeal carriage of *N. meningitdis* and are all acceptable antimicrobial agents for chemoprophylaxis (*141–144*). Systemic antimicrobial therapy of meningococcal disease with agents other than ceftriaxone or other third-generation cephalosporins might not reliably eradicate nasopharyngeal carriage of *N. meningitdis*. If other agents have been used for treatment, the index patient should receive chemoprophylactic antibiotics for eradication of nasopharyngeal carriage before being discharged from the hospital (*145*).

One recent study has reported that a single 500-mg oral dose of azithromycin was effective in eradicating nasopharyngeal carriage of *N. meningitdis* (*146*). Azithromycin, in addition to being safe and easy to administer, is also available in a suspension form and is approved for use among children. Further evaluation is warranted of both the effectiveness of azithromycin in eradicating carriage of *N. meningitdis* and potential for development of microbial resistance to this drug if it is widely used for chemoprophylaxis.

References

1. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein–polysaccharide conjugate vaccine. N Engl J Med 2003;348:1737–46.
2. Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995. N Engl J Med 1997;337:970–6.
3. CDC. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2000;49(No. RR-7):1–10.
4. CDC. Control and prevention of meningococcal disease and Control and prevention of serogroup C meningococcal disease: evaluation and management of suspected outbreaks; recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997;46(No. RR-5):1–21.
5. CDC. Meningococcal disease and college students: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2000;49(No. RR-7):11–20.
6. Jackson LA, Tenover FC, Baker C, et al. Prevalence of *Neisseria meningitidis* relatively resistant to penicillin in the United States, 1991. Meningococcal Disease Study Group. J Infect Dis 1994;169:438–41.
7. Rosenstein NE, Stocker SA, Popovic T, Tenover FC, Perkins BA, Active Bacterial Core Surveillance Team. Antimicrobial resistance of *Neisseria meningitidis* in the United States, 1997. Clin Infect Dis 2000;30:212–3.
8. Edwards MS, Baker CJ. Complications and sequelae of meningococcal infections in children. J Pediatr 1981;99:540–5.
9. Kirsch EA, Barton RP, Kitchen L, Giroir BP. Pathophysiology, treatment and outcome of meningococcemia: a review and recent experience. Pediatr Infect Dis J 1996;15:967–79.
10. Jackson LA, Schuchat A, Reeves MW, Wenger JD. Serogroup C meningococcal outbreaks in the United States: an emerging threat. JAMA 1995;273:383–9.
11. Brooks RB, Woods CW, Rosenstein NE. *Neisseria meningitidis* outbreaks in the United States, 1994–2002 [Abstract 289]. In: Abstracts of the 41st Annual Meeting of the Infectious Diseases Society of America, San Diego, CA, October 9–12, 2003:81–2.
12. Jackson LA, Wenger JD. Laboratory-based surveillance for meningococcal disease in selected areas, United States, 1989–1991. In: CDC Surveillance Summaries, June 4, 1993. MMWR 1993;42(No. SS-2): 21–30.
13. Rosenstein NE, Perkins BA, Stephens DS, et al. The changing epidemiology of meningococcal disease in the United States, 1992–1996. J Infect Dis 1999;180:1894–901.
14. Fischer M, Perkins BA. *Neisseria meningitidis* serogroup B: emergence of the ET-5 complex. Semin Pediatr Infect Dis 1997;8:50–6.
15. Figueroa JE, Densen P. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 1991;4:359–95.
16. Platonov AE, Vershinina IV, Kuijper EJ, Borrow R, Kayhty H. Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine. Vaccine 2003;21:4437–47.
17. Francke EL, Neu HC. Postsplenectomy infection. Surg Clin North Am 1981;61:135–55.
18. Fischer M, Harrison L, Farley M, et al. Risk factors for sporadic meningococcal disease in North America [Abstract 552 Fr]. In: Abstracts of the 36th Annual Meeting of the Infectious Diseases Society of America, Denver, CO, November 12–15, 1998.
19. Fischer M, Hedberg K, Cardosi P, et al. Tobacco smoke as a risk factor for meningococcal disease. Pediatr Infect Dis J 1997;16:979–83.
20. Stephens DS, Hajjeh RA, Baughman WS, Harvey RC, Wenger JD, Farley MM. Sporadic meningococcal disease in adults: results of a 5-year population-based study. Ann Intern Med 1995;123:937–40.
21. Cartwright KA, Jones DM, Smith AJ, Stuart JM, Kaczmarski EB, Palmer SR. Influenza A and meningococcal disease. Lancet 1991;338:554–7.
22. Moore PS, Hierholzer J, DeWitt W, et al. Respiratory viruses and mycoplasma as cofactors for epidemic group A meningococcal meningitis. JAMA 1990;264:1271–5.
23. Stanwell-Smith RE, Stuart JM, Hughes AO, Robinson P, Griffin MB, Cartwright K. Smoking, the environment and meningococcal disease: a case control study. Epidemiol Infect 1994;112:315–28.
24. Stuart JM, Cartwright KA, Dawson JA, Richard J, Noah ND. Risk factors for meningococcal disease: a case control study in south west England. Community Med 1988;10:139–46.
25. Zeitz P, Jafari H, Kioski C, et al. A cluster of *Neisseria meningitidis* serogroup C disease in Phoenix: risk factors for disease [Abstract 1388]. In: Programs and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, October 17–20, 1993.
26. Imrey PB, Jackson LA, Ludwinski PH, et al. Meningococcal carriage, alcohol consumption, and campus bar patronage in a serogroup C meningococcal disease outbreak. J Clin Microbiol 1995;33:3133–7.
27. Imrey PB, Jackson LA, Ludwinski PH, et al. Outbreak of serogroup C meningococcal disease associated with campus bar patronage. Am J Epidemiol 1996;143:624–30.
28. Cookson ST, Corrales JL, Lotero JO, et al. Disco fever: epidemic meningococcal disease in northeastern Argentina associated with disco patronage. J Infect Dis 1998;178:266–9.
29. Bruce MG, Rosenstein NE, Capparella JM, Shutt KA, Perkins BA, Collins M. Risk factors for meningococcal disease in college students. JAMA 2001;286:688–93.
30. Harrison LH, Dwyer DM, Maples CT, Billmann L. Risk of meningococcal infection in college students. JAMA 1999;281:1906–10.
31. Froeschle J. Meningococcal disease in college students. Clin Infect Dis 1999;29:215–6.

68. Makela PH, Peltola H, Kayhty H, et al. Polysaccharide vaccines of group A *Neisseria meningitidis* and *Haemophilus influenzae* type b: a field trial in Finland. J Infect Dis 1977;136 (Suppl):S43–50.

69. Hankins WA, Gwaltney JM Jr., Hendley JO, Farquhar JD, Samuelson JS. Clinical and serological evaluation of a meningococcal polysaccharide vaccine groups A, C, Y, and W135. Proc Soc Exp Biol Med 1982;169:54–7.

70. Roberts JS, Bryett KA. Incidence of reactions to meningococcal A&C vaccine among U.K. schoolchildren. Public Health 1988;102:471–6.

71. Yergeau A, Alain L, Press R, Robert Y. Adverse events temporally associated with meningococcal vaccines. CMAJ 1996;154:503–7.

72. Stein KE. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis 1992;165(Suppl):S49–52.

73. Gold R, Lepow ML, Goldschneider I, Gotschlich EC. Immune response of human infants to polysaccharide vaccines of groups A and C *Neisseria meningitidis*. J Infect Dis 1977;136(Suppl):S31–5.

74. King JW, MacDonald NE, Wells G, et al. Total and functional antibody response to a tetravalent meningococcal polysaccharide vaccine among children. J Pediatr 1996;128:196–202.

75. Maslanka SE, Tappero JW, Plikaytis BD, et al. Age-dependent *Neisseria meningitidis* serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine. Infect Immun 1998;66:2453–9.

76. Hassan-King MK, Wall RA, Greenwood BM. Meningococcal carriage, meningococcal disease and vaccination. J Infect 1988;16:55–9.

77. Moore PS, Harrison LH, Telzak EE, Ajello GW, Broome CV. Group A meningococcal carriage in travelers returning from Saudi Arabia. JAMA 1988;260:2686–9.

78. Frasch CE. Regulatory perspectives in vaccine licensure [Chapter 24]. In: Ellis RW, Granoff DM, eds. Development and clinical uses of *Haemophilus* b conjugate vaccines. New York, NY: Marcel Dekker, Inc.; 1994:435–53.

79. Adams WG, Deaver KA, Cochi SL, et al. Decline of childhood *Haemophilus influenzae* type b disease in the Hib vaccine era. JAMA 1993;269:221–6.

80. O'Brien KL, Brondson GM, Carlone RR, et al. Effect of a 7-valent pneumococcal conjugate vaccine on nasopharyngeal (NP) carriage among Navajo and White Mountain Apache (N/WMA) infants [Abstract]. Presented at the 19th Annual Meeting of the European Society of Paediatric Infectious Diseases (ESPID), Istanbul, Turkey; March 26–28, 2001.

81. Takala AK, Eskola J, Leinonen M, et al. Reduction of oropharyngeal carriage of *Haemophilus influenzae* type b (Hib) in children immunized with an Hib conjugate vaccine. J Infect Dis 1991;164:982–6.

82. Mohle-Boetani JC, Ajello G, Breneman E, et al. Carriage of *Haemophilus influenzae* type b in children after widespread vaccination with conjugate *Haemophilus influenzae* type b vaccines. Pediatr Infect Dis J 1993;12:589–93.

83. Richmond P, Borrow R, Goldblatt D, et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis 2001;183:160–3.

84. Burrage M, Robinson A, Borrow R, et al. Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. Infect Immun 2002;70:4946–54.

85. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001;20 (Suppl 1):S58–67.

86. Ramsay M, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003;326:365–6.

87. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004;364:365–7.

88. Ramsay ME, Andrews N, Kaczmarski EB, Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 2001;357:195–6.

89. Bose A, Coen P, Tully J, Viner R, Booy R. Effectiveness of meningococcal C conjugate vaccine in teenagers in England. Lancet 2003;361:675–6.

90. Maiden MC, Stuart JM; UK Meningococcal Carriage Group. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002;359:1829–31.

91. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I: The role of humoral antibodies. J Exp Med 1969;129:1307–26.

92. Borrow R, Andrews N, Goldblatt D, Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluaiton of correlates of protection. Infect Immun 2001;69:1568–73.

93. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol 2003;10:780–6.

94. Trotter CL, Borrow R, Andrews N, Miller E. Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era. Vaccine 2003;21:1094–8.

95. Jodar L, Griffiths E, Feavers I. Scientific challenges for the quality control and production of group C meningococcal conjugate vaccines. Vaccine 2004;22:1047–53.

96. Sippel JE. Meningococci. Crit Rev Microbiol 1981;8:267–302.

97. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee, September 22, 2004: briefing information. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration; 2004. Available at http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4072b1.htm.

98. Food and Drug Administration. Product approval information—licensing action. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; 2005. Available at http://www.fda.gov/cber/products/mpdtave011405.htm.

99. Ruben FL, Froeschle JE, Meschievitz C, et al. Choosing a route of administration for tetravalent meningococcal polysaccharide vaccine: intramuscular versus subcutaneous. Clin Infect Dis 2001;32:170–2.

100. Scott RD 2nd, Meltzer MI, Erickson LJ, De Wals P, Rosenstein NE. Vaccinating first-year college students living in dormitories for meningococcal disease: an economic analysis. Am J Prev Med 2002;23:98–105.

101. Jackson LA, Schuchat A, Gorsky RD, Wenger JD. Should college students be vaccinated against meningococcal disease? A cost-benefit analysis. Am J Public Health 1995;85:843–5.

102. Shepard CW, Ortega-Sanchez I, Corso P, Scott D, Rosenstein N, ABCs Team. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States [Abstract LB-5]. In: Final program and abstracts, 42nd Annual Meeting of IDSA, Boston, MA, September 30–October 3, 2004.

103. Balmer P, Borrow R, Miller E. Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol 2002;51:717–22.

104. Lieu T, Ray GT, Black SB, et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA 2000;283:1460–8.

105. Zhou F, Bisgard KM, Yusuf HR, Deuson RR, Bath SK, Murphy TV. Impact of universal *Haemophilus influenzae* type b vaccination starting at 2 months of age in the United States: an economic analysis. Pediatrics 2002 Oct;110:653–1.

106. Committee on Practice and Ambulatory Medicine. Recommendations for preventative pediatric health care. Pediatrics 2000;105:645–6.

107. CDC. Immunization of adolescents: recommendations of the Advisory Committee on Immunization Practices, Academy of Pediatrics, the American Academy of Physicians, and the American Medical Association. MMWR 1996;45(No. RR-13):1–16.

108. Elster A. Guidelines for adolescent preventive services [Internet site]. Wellesley, MA: UpToDate; 2004. Available at http://patients.uptodate.com/topic.asp?file=adol_med/2634.

109. Elster AB, ed. AMA guidelines for adolescent preventive services (GAPS): recommendations and rationale. Baltimore, MD: Williams & Wilkins; 1994.

110. CDC. Laboratory-acquired meningococcal disease—United States, 2000. MMWR 2002;51:141–4.

111. Brundage JF, Zollinger WD. Evolution of meningococcal disease epidemiology in the U.S. Army. In: Vedros NA, ed. Evolution of meningococcal disease, volume 1. Boca Raton, FL: CRC Press, Inc.; 1987:5–25.

112. Riedo FX, Plikaytis BD, Broome CV. Epidemiology and prevention of meningococcal disease. Pediatr Infect Dis J 1995;14:643–57.

113. Fijen CA, Kuijper EJ, Drogari-Apiranthitou M, Van Leeuwen Y, Daha MR, Dankert J. Protection against meningococcal serogroup ACYW disease in complement-deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine. Clin Exp Immunol 1998;114:362–9.

114. Nuorti JP, Butler JC, Gelling L, Kool JL, Reingold AL, Vugia DJ. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. Ann Intern Med 2000;132:182–90.

115. Campbell JD, Edelman R, King JC Jr, Papa T, Ryall R, Rennels MB. Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adults. J Infect Dis 2002;186:1848–51.

116. Keyserling H, Rothstein E, Blatter M, Ryall R, Bybel M, Papa T. Augmentation of the immune response to a tetravalent meningococcal (A, C, Y, W-135) diphtheria conjugate vaccine (MCV-4) by co-administration with tetanus-diphtheria vaccine (Td) in healthy adolescents [Abstract 1044]. In: Final program and abstracts of the 42nd Annual Meeting of IDSA, Boston, MA, September 30–October 3, 2004.

117. CDC. General recommendations on immunization. MMWR 2002;51(No. RR-2):1–36.

118. Borrow R, Southern J, Andrews N, et al. Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naïve controls. Vaccine 2001;19:3043–50.

119. Richmond P, Kaczmarski E, Borrow R, et al. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis 2000;181:761–4.

120. Goldblatt D, Borrow R, Miller E. Natural and vaccine-induced immunity and immunologic memory to *Neisseria meningitidis* serogroup C in young adults. J Infect Dis 2002;185:397–400.

121. Leston GW, Little JR, Ottman J, Miller GL. Meningococcal vaccine in pregnancy: an assessment of infant risk. Pediatr Infect Dis J 1998;17:261–3.

122. McCormick JB, Gusmao HH, Nakamura S, et al. Antibody response to serogroup A and C meningococcal polysaccharide vaccines in infants born of mothers vaccinated during pregnancy. J Clin Invest 1980;65:1141–4.

123. de Andrade Carvalho A, Giampaglia CM, Kimura H, et al. Maternal and infant antibody response to meningococcal vaccination in pregnancy. Lancet 1977;2:809–11.

124. Rennels M, King J Jr, Ryall R, et al. Dose escalation, safety and immunogenicity study of a tetravalent meningococcal polysaccharide diphtheria conjugate vaccine in toddlers. Pediatr Infect Dis 2002;21:978–9.

125. Rennels M, King J Jr, Ryall R, Papa T, Froeschle J. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr Infect Dis J 2004;23:429–35.

126. Pichichero M, Casey J, Blatter M, et al. Comparative trial of the safety and immunogenicity of tetravalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus tetravalent polysaccharide vaccine in two- to ten-year-old children. Pediatr Infect Dis J 2005;24:57–62.

127. de Moraes JC, Perkins BA, Camargo MC, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992;340:1074–8.

128. Boslego J, Garcia J, Cruz C, et al. Efficacy, safety, and immunogenicity of a meningococcal vaccine group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine 1995;13:821–9.

129. Bjune G, Hoiby EA, Gronnesby JK, et al. Effect of outer membrane vesicle vaccine against group b meningococcal disease in Norway. Lancet 1991;338:1093–6.

130. Sierra GV, Campa HC, Varcacel NM, et al. Vaccine against group B *Neisseria meningitidis*: protection trial and mass vaccination results in Cuba. NIPH Ann 1991;14:195–210.

131. Cartwright K, Morris R, Rumke H, et al. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine 1999;17:2612–9.

132. Tondella ML, Popovic T, Rosenstein NE, et al. Distribution of *Neisseria meningitidis* serogroup B serosubtypes and serotypes circulating in the United States. The active Bacterial Core Surveillance Team. J Clin Microbiol 2000;38:3323–8.

133. Parkhill J, Achtman M, James KD, et al. Complete DNA sequence of a serogroup A strain of *Neisseria meningitidis* Z2491. Nature 2000;404:451–2.

134. Morley SL, Pollard AJ. Vaccine prevention of meningococcal disease, coming soon? Vaccine 2002;20:666–87.

135. Fusco PC, Michon F, Tai JY, Blake MS. Preclinical evaluation of a novel group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and nonhuman primates. J Infect Dis 1997;175:364–72.

136. De Wals P, Hertoghe L, Borlee-Grimee I, et al. Meningococcal disease in Belgium. Secondary attack rate among household, day-care nursery and pre-elementary school contacts. J Infect 1981;3 (1 Suppl):53–61.

137. Anonymous. Analysis of endemic meningococcal disease by serogroup and evaluation of chemoprophylaxis. The meningococcal disease surveillance group. J Infect Dis 1976;134:201–4.

138. Jacobson JA, Filice GA, Holloway JT. Meningococcal disease in day-care centers. Pediatrics 1977;59:299–300.

139. CDC. Guidelines for the management of airline passengers exposed to meningococcal disease. Atlanta, GA: US Department of Health and Human Services, CDC; 2000. Available at http://www.cdc.gov/travel/menin-guidelines.htm.

140. Gilmore A, Stuart J, Andrews N. Risk of secondary meningococcal disease in health-care workers. Lancet 2000;356:1654–5.

141. Dworzack DL, Sanders CC, Horowitz EA, et al. Evaluation of single-dose ciprofloxacin in the eradication of *Neisseria meningitidis* from nasopharyngeal carriers. Antimicrob Agents Chemother 1988;32:1740–1.

142. Schwartz B, Al-Tobaiqi A, Al-Ruwais A, et al. Comparative efficacy of ceftriaxone and rifampin in eradicating pharyngeal carriage of group A *Neisseria meningitidis*. Lancet 1988;1:1239–42.

143. Gaunt P, Lambert BE. Single dose ciprofloxacin for the eradication of pharyngeal carriage of *Neisseria meningitidis*. J Antimicrob Chemo 1988;21:489–96.

144. Broome CV. The carrier state: *Neisseria meningitidis*. J Antimicrob Chemo 1986;18(Suppl A):25–34.

145. Abramson JS, Spika JS. Persistence of *Neisseria meningitidis* in the upper respiratory tract after intravenous antibiotic therapy for systemic meningococcal disease. J Infect Dis 1985;151:370–1.

146. Girgis N, Sultan Y, Frenck RW Jr, El-Gendy A, Farid Z, Matezcun A. Azithromycin compared with rifampin for eradication of nasopharyngeal colonization by *Neisseria meningitidis*. Pediatr Infect Dis J 1998;17:816–9.

Recommendations and Reports   **May 27, 2005 / Vol. 54 / No. RR-7**

Continuing Education Activity Sponsored by CDC
Prevention and Control of Meningococcal Disease

Recommendations of the Advisory Committee on Immunization Practices (ACIP)

EXPIRATION — May 27, 2008

You must complete and return the response form electronically or by mail by **May 27, 2008**, to receive continuing education credit. If you answer all of the questions, you will receive an award letter for 3.25 hours Continuing Medical Education (CME) credit; 0.3 Continuing Education Units (CEUs); or 3.8 contact hours Continuing Nursing Education (CNE) credit. If you return the form electronically, you will receive educational credit immediately. If you mail the form, you will receive educational credit in approximately 30 days. No fees are charged for participating in this continuing education activity.

INSTRUCTIONS

By Internet

1. Read this *MMWR* (Vol. 54, RR-7), which contains the correct answers to the questions beginning on the next page.
2. Go to the *MMWR* Continuing Education Internet site at http://www.cdc.gov/mmwr/cme/conted.html.
3. Select which exam you want to take and select whether you want to register for CME, CEU, or CNE credit.
4. Fill out and submit the registration form.
5. Select exam questions. To receive continuing education credit, you must answer all of the questions. Questions with more than one correct answer will instruct you to "Indicate all that apply."
6. Submit your answers no later than **May 27, 2008**.
7. Immediately print your Certificate of Completion for your records.

By Mail or Fax

1. Read this *MMWR* (Vol. 54, RR-7), which contains the correct answers to the questions beginning on the next page.
2. Complete all registration information on the response form, including your name, mailing address, phone number, and e-mail address, if available.
3. Indicate whether you are registering for CME, CEU, or CNE credit.
4. Select your answers to the questions, and mark the corresponding letters on the response form. To receive continuing education credit, you must answer all of the questions. Questions with more than one correct answer will instruct you to "Indicate all that apply."
5. Sign and date the response form or a photocopy of the form and send no later than **May 27, 2008**, to
   Fax: 770-488-8555   Mail: MMWR CE Credit
   Division of Scientific Communications
   Coordinating Center for Health Information
   and Service, MS K-95
   Centers for Disease Control and Prevention
   1600 Clifton Rd, N.E.
   Atlanta, GA 30333
6. Your Certificate of Completion will be mailed to you within 30 days.

ACCREDITATION

Continuing Medical Education (CME). CDC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. CDC designates this educational activity for a maximum of 3.25 hours in category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Continuing Education Unit (CEU). CDC has been approved as an authorized provider of continuing education and training programs by the International Association for Continuing Education and Training and awards 0.3 Continuing Education Units (CEUs).

Continuing Nursing Education (CNE). This activity for 3.8 contact hours is provided by CDC, which is accredited as a provider of continuing education in nursing by the American Nurses Credentialing Center's Commission on Accreditation.

Goal and Objectives

This report provides recommendations on use of the newly licensed tetravalent meningococcal polysaccharide-protein conjugate vaccine (MCV4). The recommendations were developed by CDC's Advisory Committee on Immunization Practices (ACIP). The goal of this report is to provide recommendations for clinicians, public health officials, and other persons concerned with controlling and preventing meningococcal disease in the United States on the use of MCV4 and to update previous ACIP recommendations on prevention and control of meningococcal disease, including recommendations on use of the tetravalent meningococcal polysaccharide vaccine (MPSV4). Upon completion of this educational activity, the reader should be able to 1) describe the epidemiology of meningococcal disease in the United States; 2) describe the differences between polysaccharide and polysaccharide-protein conjugate meningococcal vaccines; 3) identify the populations for which MCV4 and MPSV4 are recommended; 4) describe the principles of evaluation and management of suspected outbreaks of meningococcal disease; and 5) identify indications with appropriate drug schedules for antimicrobial chemoprophylaxis of meningococcal disease.

To receive continuing education credit, please answer all of the following questions.

1. **MCV4 and MPSV4 are not expected to be effective in preventing meningococcal disease caused by which serogroup of *Neisseria meningitidis*?**
   A. A.
   B. B.
   C. C.
   D. Y.
   E. W-135.

2. **Which three serogroups of *N. meningitidis* are responsible for the majority cases of invasive meningococcal disease occurring in the United States?**
   A. A, B, and C.
   B. B, C, and Y.
   C. C, Y, and W-135.
   D. A, B, and Y.
   E. A, C, and W-135.

3. **Which group of U.S. college students is at highest risk for meningococcal disease?**
   A. College students living in dormitories.
   B. College freshmen.
   C. Nonfreshmen.
   D. College freshmen living in dormitories.
   E. Nonfreshmen living in dormitories.

4. **Which of the following antibiotics is not recommended for chemoprophylaxis of the close contacts of patients with invasive meningococcal disease?**
   A. Ciprofloxacin.
   B. Amoxicillin.
   C. Ceftriaxone.
   D. Rifampin.

5. **For which age groups is MCV4 currently licensed in the United States?**
   A. 0–5 years.
   B. 11–25 years.
   C. ≥2 years.
   D. 11–55 years.
   E. ≥18 years.

6. **Which of the following populations is not considered at increased risk for meningococcal disease?**
   A. Military recruits.
   B. Travelers to areas where an epidemic of meningococcal disease is occurring.
   C. Middle school students.
   D. College students living in dormitories.

   E. Persons who have terminal complement component deficiency.

7. **Which vaccine is recommended for young adolescents aged 11–12 years at the preadolescent assessment visit and of adolescents at high school entry?**
   A. MCV4.
   B. MPSV4.
   C. Both MCV4 and MPSV4.
   D. MCV4 is preferred, but MPSV4 is also acceptable.
   E. MPSV4 is preferred, but MCV4 is also acceptable.

8. **Which vaccine is recommended for vaccination of patients aged 60 years with anatomic asplenia?**
   A. MCV4.
   B. MPSV4.
   C. Both MCV4 and MPSV4.
   D. MCV4 is preferred, but MPSV4 is also acceptable.
   E. Neither MCV4 nor MPSV4 is recommended.

9. **What are the expected characteristics of MCV4 and other polysaccharide-protein conjugate vaccines?**
   A. Stimulate a T-cell–dependent immune system response.
   B. Induce immunologic memory.
   C. Confer protection in young children aged <2 years.
   D. Reduce carriage of meningococcal serogroups included in the vaccine.
   E. All of the above.

10. **Who of the following is not considered a close contact of the patient with meningococcal disease (and thus does not require chemoprophylaxis)?**
   A. Mother of the patient living in the same house.
   B. Co-worker who works in the office across the hall from the patient.
   C. Person whom the patient was kissing frequently.
   D. Child aged 2 years attending the same child care center as the patient.
   E. Doctor who conducted endotracheal intubation when the patient was hospitalized.

11. **Which best describes your professional activities?**
   A. Physician.
   B. Nurse.
   C. Health educator.
   D. Office staff.
   E. Other.

12. **I plan to use these recommendations as the basis for . . . (*Indicate all that apply.*)**
   A. health education materials.
   B. insurance reimbursement policies.
   C. local practice guidelines.
   D. public policy.
   E. other.

13. Each month, approximately how many vaccinations for meningococcal disease do you administer?
   A. None.
   B. 1–5.
   C. 6–20.
   D. 21–50.
   E. 51–100.
   F. >100.

14. How much time did you spend reading this report and completing the exam?
   A. <2.0 hours.
   B. >2.0 hours but <3.0 hours.
   C. >3.0 hours but <4.0.
   D. >4.0 hours.

15. After reading this report, I am confident I can describe the epidemiology of meningococcal disease in the United States.
   A. Strongly agree.
   B. Agree.
   C. Neither agree nor disagree.
   D. Disagree.
   E. Strongly disagree.

16. After reading this report, I am confident I can describe the differences between polysaccharide and polysaccharide-protein conjugate meningococcal vaccines.
   A. Strongly agree.
   B. Agree.
   C. Neither agree nor disagree.
   D. Disagree.
   E. Strongly disagree.

17. After reading this report, I am confident I can identify the populations for which MCV4 and MPSV4 are recommended.
   A. Strongly agree.
   B. Agree.
   C. Neither agree nor disagree.
   D. Disagree.
   E. Strongly disagree.

18. After reading this report, I am confident I can describe the principles of evaluation and management of suspected outbreaks of meningococcal disease.
   A. Strongly agree.
   B. Agree.
   C. Neither agree nor disagree.
   D. Disagree.
   E. Strongly disagree.

19. After reading this report, I am confident I can identify indications with appropriate drug schedules for antimicrobial chemoprophylaxis of meningococcal disease.
   A. Strongly agree.
   B. Agree.
   C. Neither agree nor disagree.
   D. Disagree.
   E. Strongly disagree.

20. The objectives are relevant to the goal of this report.
   A. Strongly agree.
   B. Agree.
   C. Neither agree nor disagree.
   D. Disagree.
   E. Strongly disagree.

Detach or photocopy.

MMWR Response Form for Continuing Education Credit
May 27, 2005/Vol. 54/No. RR-7
Prevention and Control of Meningococcal Disease
Recommendations of the Advisory Committee on Immunization Practices (ACIP)

To receive continuing education credit, you must
1. provide your contact information (please print or type);
2. indicate your choice of CME, CME for nonphysicians, CEU, or CNE credit;
3. answer all of the test questions;
4. sign and date this form or a photocopy;
5. submit your answer form by May 27, 2008.
Failure to complete these items can result in a delay or rejection of your application for continuing education credit.

Check One
☐ CME Credit
☐ CME for nonphysicians Credit
☐ CEU Credit
☐ CNE Credit

Last Name (print or type) ___ First Name ___
Street Address or P.O. Box ___
Apartment ___ or ___ Suite ___
City ___ State ___ ZIP Code ___
Phone Number ___ Fax Number ___
E-Mail Address ___

Fill in the appropriate blocks to indicate your answers. Remember, you must answer all of the questions to receive continuing education credit!

1. [ ]A	[ ]B	[ ]C	[ ]D	[ ]E		14. [ ]A	[ ]B	[ ]C	[ ]D	[ ]E
2. [ ]A	[ ]B	[ ]C	[ ]D	[ ]E		15. [ ]A	[ ]B	[ ]C	[ ]D	[ ]E
3. [ ]A	[ ]B	[ ]C	[ ]D	[ ]E		16. [ ]A	[ ]B	[ ]C	[ ]D	[ ]E
4. [ ]A	[ ]B	[ ]C	[ ]D			17. [ ]A	[ ]B	[ ]C	[ ]D	[ ]E
5. [ ]A	[ ]B	[ ]C	[ ]D	[ ]E		18. [ ]A	[ ]B	[ ]C	[ ]D	[ ]E
6. [ ]A	[ ]B	[ ]C	[ ]D	[ ]E		19. [ ]A	[ ]B	[ ]C	[ ]D	[ ]E
7. [ ]A	[ ]B	[ ]C	[ ]D	[ ]E		20. [ ]A	[ ]B	[ ]C	[ ]D	[ ]E
8. [ ]A	[ ]B	[ ]C	[ ]D	[ ]E		21. [ ]A	[ ]B	[ ]C	[ ]D	[ ]E
9. [ ]A	[ ]B	[ ]C	[ ]D	[ ]E		22 [ ]A	[ ]B	[ ]C	[ ]D	[ ]E
10. [ ]A	[ ]B	[ ]C	[ ]D	[ ]E		23. [ ]A	[ ]B	[ ]C	[ ]D	[ ]E
11. [ ]A	[ ]B	[ ]C	[ ]D	[ ]E		24. [ ]A	[ ]B	[ ]C	[ ]D	[ ]E
12 [ ]A	[ ]B	[ ]C	[ ]D	[ ]E		25. [ ]A	[ ]B	[ ]C	[ ]D	[ ]E
13. [ ]A	[ ]B	[ ]C	[ ]D	[ ]E	[ ]F	26. [ ]A	[ ]B	[ ]C	[ ]D	[ ]E	[ ]F

Signature ___ Date I Completed Exam ___

21. **The teaching strategies used in this report (text, figures, and tables) were useful.**
    A. Strongly agree.
    B. Agree.
    C. Neither agree nor disagree.
    D. Disagree.
    E. Strongly disagree.

22. **Overall, the presentation of the report enhanced my ability to understand the material.**
    A. Strongly agree.
    B. Agree.
    C. Neither agree nor disagree.
    D. Disagree.
    E. Strongly disagree.

23. **These recommendations will affect my practice.**
    A. Strongly agree.
    B. Agree.
    C. Neither agree nor disagree.
    D. Disagree.
    E. Strongly disagree.

24. **The content of this activity was appropriate for my educational needs.**
    A. Strongly agree.
    B. Agree.
    C. Neither agree nor disagree.
    D. Disagree.
    E. Strongly disagree.

25. **The availability of continuing education credit influenced my decision to read this report.**
    A. Strongly agree.
    B. Agree.
    C. Neither agree nor disagree.
    D. Disagree.
    E. Strongly disagree.

26. **How did you learn about this continuing education activity?**
    A. Internet.
    B. Advertisement (e.g., fact sheet, *MMWR* cover, newsletter, or journal).
    C. Coworker/supervisor.
    D. Conference presentation.
    E. *MMWR* subscription.
    F. Other.

Correct answers for questions 1–10.
1. B; 2. B; 3. D; 4. B; 5. D; 6. C; 7. A; 8. B; 9. E; 10. B.